



# ONE STOP SOLUTION FOR ALL CRITICAL CARE MEDICINE LEARNING

## “MASTER CLASSES IN CRITICAL CARE MEDICINE”

(one and only successfully running digital learning platform in critical care medicine throughout the globe)

Dear all after the huge success of previous batches of “Master Classes in Critical Care Medicine” ,we are happy to announce the schedule of 12th batch from January 2025.



**“FOR PREVIOUS BATCH DELEGATES- Registration amount - Rs 18,000 (220 USD) plus 18%GST”**

**“FOR FIRST 100 REGISTRATIONS (for those who are not part of previous batches)-  
Registration amount - Rs 22,500 (270 USD) plus 18%GST”**

Now around  
**250 topics**  
included

(Above discount is valid till 31st December 2024)

{Regular price after the discounted period -Rs 30,000(365 USD) plus 18%GST}

### Additional Features of batch twelve

- All the recorded version of the classes will be available from first day of your registration to watch as per your convenience for the entire tenure of the course (from the start date of the course to end of the course) on mobile/laptop/desktop with the individual login details
- To cover theory/practical points/MCQs of entire critical care medicine topics
- 10 Mock Tests with explanation of the answers included
- Case based approach to help CTCCM/IDCCM/IFCCM, EDIC/EDIAC II and DM/DrNB exit exams
- To discuss MCQs according to new pattern of NEET-SS and INI-CET critical care super speciality entrance exam
- Round the clock, one to one doubt clarification – to help practicing intensivists/anaesthetists/physicians/pulmonologists/emergency physicians
- Continued academic support to registered delegates through “VOICE OF CRITICAL CARE MEDICINE” even after the batch is over
- With many more newer topics and MCQs included

### Who should attend ?

- Those who are practicing Critical Care Medicine, Anaesthesia, Pulmonology, General Medicine and Emergency Medicine and interested to learn and upgrade the knowledge in critical care medicine.
- Those who are doing postgraduation in Anaesthesia, Pulmonology, General Medicine and Emergency Medicine and interested to choose Critical Care as career option.
- Those who are doing CTCCM, IDCCM, IFCCM, PDCC, FNB/DNB, DM in critical care.
- Those who are preparing for EDIC/EDIAC part I & II.
- Those who are preparing for NEET super speciality and INISS-CET entrance.



**Scan QR Code  
to register**

### COURSE FACULTY & DIRECTOR

#### Dr Harish Mallapura Maheshwarappa

MBBS, MD, DNB, IDCCM, DM (Critical Care Medicine TMH, Mumbai),  
EDIC(Dublin), Fellowship in Infectious Diseases, FIARC, MBA  
Intensive Care Physician and Infectious Disease Specialist

Mail : dr.harishmm@rocketmail.com

Call : +91-80952 18493

web : <https://harishcriticalcareclasses.com/>



**Classes will be starting  
from January 2025**

For technical Queries call : +91 95381 15187

## CURRICULUM

(now around 250 topics included)

### INFECTIONS AND ANTI – INFECTIVES

1. SEPSIS – A CASE BASED APPROACH
2. SEPSIS GUIDELINES 2021- WHAT'S NEW?
3. EMPERIC ANTIBIOTIC APPROACH AND ANTIBIOTIC DEESCALATION IN ICU
4. COMMUNITY ACQUIRED PNEUMONIA
5. INVASIVE FUNGAL INFECTIONS – A CASE BASED APPROACH
6. NEWER ANTIBIOTICS IN THE PIPELINE
7. MDR GRAM NEGATIVES IN ICU: BASICS AND BEYOND
8. DIFFERENTIAL USAGE OF CARBAPENAMS: CURRENT EVIDENCE
9. APPROACH TO TROPICAL INFECTIONS IN ICU
10. "PK – PD OF ANTIBIOTICS IN CRITICALLY ILL PATIENTS"
11. INTERPRETATION OF CULTURE SENSITIVITY REPORT: –MIC, BPC, MPC WHAT TO SEE AT THE BEDSIDE?
12. RAPID DIAGNOSTICS AND THERAPEUTIC DRUG MONITORING IN ICU : IS IT THE FUTURE?
13. TREATING HIV PATIENT : ICU PERSPECTIVE
14. INFECTION CONTROL POLICIES IN ICU:–CARING OF LINES, DRAINS AND PIPES, BIOMEDICAL WASTE MANAGEMENT, TRANSMISSION SPECIFIC ISOLATION PRECAUTIONS
15. IMMUNOMODULATION IN ICU WHAT IS THE EVIDENCE:–ULINASTATIN, METHYLENE BLUE , SEPSIVAC, THYMOICIN ALPHA, INTERFERON ALPHA MARIK'S PROTOCOL
16. MANAGING COMPLICATED UTI: AN OVERVIEW
17. OXA 48 AN EMERGING THREAT: WHAT WE SHOULD KNOW?
18. PULMONARY TB IN ICU: CHALLENGES IN DIAGNOSIS AND THERAPY
19. PYREXIA OF UNKNOWN ORIGIN: A PROTOCOLIZED APPROACH
20. MANAGEMENT OF COMPLICATED SKIN-SOFT TISSUE INFECTIONS IN ICU
21. CARBAPENEM RESISTANT ENTEROBACTERIACEAE AND THE OPTIONS AVAILABLE : AN OVERVIEW
22. CATHETER-RELATED BLOODSTREAM INFECTION (CRBSI) AND CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTION (CLABSI) : AN OVERVIEW
23. APPROACH TO NEW ONSET OF FEVER IN ICU

### HEAMODYNAMIC MONITORING

1. PRESSURE BASED INDECES / STATIC PARAMETERS–CVP, PAOP AND ARTERIAL LINE
2. CASE BASED DISCUSSION–VOLUME BASED INDECES / DYNAMIC PARAMETERS–PPV,SVV,SPV
3. CARDIAC OUTPUT MONITORING AN OVERVIEW
4. CARDIOGENIC SHOCK–CASE BASED APPROACH
5. OBSTRUCTIVE SHOCK–CASE BASED APPROACH
6. CASE BASED DISCUSSION- FLUID RESPONSIVENESS AND ADVANCED HEMODYNAMIC MONITORING:FLOW TRAC / VOLUME VIEW / PLR
7. FAST, eFAST, POCUS, BLUE PROTOCOL AND VEXUS SCORE: AN OVERVIEW
8. HYPOTENSION PREDICTION INDEX (HPI): NEW CONCEPT IN HEMODYNAMIC MONITORING
9. NEW CONCEPT IN HEMODYNAMIC MONITORING: PULSE WAVE TRANSIT TIME

### RESUSCITATION AND DERESUSCITATION

1. PCO2 GAP – PRACTICAL UTILITY AT THE BEDSIDE.
2. LACTATE IN NORMOTENSIVE PATIENTS : ITS CLINICAL RELEVANCE.
3. MICROCIRCULATORY ASSESSMENT IN ICU : WHERE WE ARE TODAY?
4. DE-RESUSCITATION IN ICU PATIENTS : WHEN AND WHICH PATIENTS TO BE INITIATED?

### RESUSCITATION AND DERESUSCITATION

1. TREATING ATRIAL FIBRILLATION IN ICU
2. ACUTE CORONARY SYNDROME
3. ACUTE PULMONARY EMBOLISM
4. UNDERSTANDING DIASTOLIC DYSFUNCTION : CASE BASED APPROACH
5. NEWER DRUGS TO TREAT HEART FAILURE
6. MANAGEMENT OF SEPSIS INDUCED CARDIOMYOPATHY: CURRENT EVIDENCE

## CURRICULUM

(now around 250 topics included)

7. RIGHT HEART FAILURE IN ICU: A PROTOCOLIZED APPROACH
8. MECHANICAL CIRCULATORY SUPPORT DEVICES IN ICU (IABP, LVAD, IMPELLA): AN OVER VIEW
9. ECMO BASICS
10. ACLS/BLS
11. POST CARDIAC ARREST CARE
12. PACEMAKER IN ICU

### ARDS

1. ARDS GENERAL AND VENTILATORY ASPECTS
2. LANDMARK TRIALS IN ARDS
3. UNDERSTANDING ARDS : CASE BASED APPROACH
4. AVIPTADIL -A SYNTHETIC FORM OF VASOACTIVE INTESTINAL PEPTIDE IN ARDS: CURRENT EVIDENCE
5. WHAT IS NEW IN ARDS : UNDERSTANDING DIFFERENT PHENOTYPES
6. WHAT IS NEW IN ARDS : ADJUVANT THERAPIES

### RESPIRATORY CRITICAL CARE

1. VENTILATOR ASSOCIATED PNEUMONIA
2. COPD – ICU MANAGEMENT
3. BRONCHIAL ASTHMA – ICU MANAGEMENT
4. AN EVIDENCE BASED MANAGEMENT OF COVID 19 IN ICU: AN OVERVIEW OF EVIDENCE TILL NOW
5. SYSTEMATIC APPROACH TO AIRWAY MANAGEMENT IN ICU : IS IT A DIFFERENT BALL GAME?
6. MASSIVE HEMOPTYSIS: A PROTOCOLIZED APPROACH
7. APPROACH TO PULMONARY ARTERY HYPERTENSION: AN OVERVIEW
8. TREATING PULMONARY FIBROSIS: AN EVIDENCE-BASED APPROACH
9. ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASE: AN EVIDENCE-BASED APPROACH
10. INHALED ANTI-INFECTIVES (ANTIBIOTICS AND ANTIFUNGALS) IN ICU : CURRENT EVIDENCE
11. EXTRACORPOREAL CO2 REMOVAL: WHEN AND WHICH PATIENTS?

11. EXTRACORPOREAL CO2 REMOVAL: WHEN AND WHICH PATIENTS?
12. STEPWISE APPROACH TO HYPOXIC RESPIRATORY FAILURE

### MECHANICAL VENTILATION

1. NON-INVASIVE VENTILATION:CURRENT EVIDENCE
2. HIGH FLOW NASAL CANULA: CURRENT EVIDENCE
3. BASICS OF VENTILATOR GRAPHICS
4. ADVANCED MODES OF MECHANICAL VENTILATION AN OVERVIEW
5. WEANING FAILURE AND DIFFICULTY IN WEANING
6. DIAPHRAGM PROTECTIVE VENTILATION : WHAT IT IS EXACTLY?
7. RIGHT VENTRICLE-PROTECTIVE VENTILATION : HOW TO APPROACH
8. PATIENT SELF INFLICTED LUNG INJURY : UNDERSTANDING THE NEW CONCEPT.
9. LUNG STRESS AND STRAIN IN MECHANICAL VENTILATION.

### FLUIDS, ELECTROLYTES & BLOOD

1. IV FLUID THERAPY IN ICU – CURRENT EVIDENCE
2. ALBUMIN IN ICU: WHEN, HOW MUCH AND WHICH PATIENTS?
3. APPROACH TO HYPONATREMIA
4. APPROACH TO HYPERNATREMIA
5. MASSIVE TRANSFUSION PROTOCOL AND DAMAGE CONTROLLED RESUSCITATION
6. TRALI AND TACO : AN OVERVIEW
7. AN APPROACH TO ARTERIAL BLOOD GAS ANALYSIS
8. ARTERIAL BLOOD GAS ANALYSIS PART II: STEWART'S APPROACH
9. TREATMENT OF HYPOKALEMIA IN ICU
10. TREATMENT OF HYPERKALEMIA IN ICU
11. TREATMENT OF HYPOMAGNESEMIA IN ICU
12. TREATMENT OF HYPERMAGNESEMIA IN ICU
13. TREATMENT OF HYPOPHOSPHATEMIA IN ICU

## CURRICULUM

(now around 250 topics included)

14. TREATMENT OF HYPERPHOSPHATEMIA IN ICU
15. TREATMENT OF HYPOCALCEMIA IN ICU
16. TREATMENT OF HYPERCALCEMIA IN ICU

### ENDOCRINE AND NUTRITION

1. DIABETIC EMERGENCIES IN ICU: DKA, HHS & HYPOGLYCEAMIA
2. APPROACH TO HYPOGLYCEMIA IN ICU : AN OVERVIEW
3. ACUTE ADRENAL INSUFFICIENCY: ICU MANAGEMENT
4. MANAGING HYPOTHYROIDISM AND MYXEDEMA COMA IN ICU: AN OVERVIEW
5. MANAGING HYPERTHYROIDISM AND THYROTOXICOSIS IN ICU: AN OVERVIEW
6. AN APPROACH TO ENTERAL NUTRITION IN ICU
7. DISEASE SPECIFIC NUTRITION
8. PHARMACO-NUTRITION
9. REFEEDING SYNDROME
10. TOTAL PARENTERAL NUTRITION: WHEN, HOW MUCH AND WHICH PATIENTS?

### GUT, LIVER AND PANCREAS

1. CLOSTRIDIUM DIFFICILE DIARRHEA
2. SEVERE ACUTE PANCREATITIS
3. WHAT'S NEW IN THE MANAGEMENT OF ACUTE SEVERE PANCREATITIS IN THE ICU
4. ACUTE FULMINANT LIVER FAILURE
5. ABDOMINAL COMPARTMENT SYNDROME
6. ICU MANAGEMENT OF UPPER GASTROINTESTINAL BLEED
7. ICU MANAGEMENT OF LOWER GASTROINTESTINAL BLEED

### NEURO CRITICAL CARE

1. SUB ARACHNOID BLEED
2. MANAGING STROKE : ICU PERSPECTIVE
3. GB SYNDROME
4. MYASTHENIA GRAVIS
5. ICU ACQUIRED WEAKNESS
6. TREATING MENINGITIS: ICU PERSPECTIVES
7. A STEPWISE APPROACH TO REFRACTORY STATUS EPILEPTICUS
8. AUTO IMMUNE ENCEPHALITIS: ICU PERSPECTIVE
9. ENCEPHALOPATHY IN ICU: METABOLIC
10. ENCEPHALOPATHY IN ICU: SEPTIC
11. TRANSCRANIAL DOPPLER AND ICP MONITORING: AN OVERVIEW
12. BRAIN DEATH DECLARATION AND ORGAN PRESERVATION
13. MANAGING HEATSTROKE IN ICU : AN OVERVIEW
14. APPROACH TO AN UNCONSCIOUS PATIENT : AN OVERVIEW

### ONCO CRITICAL CARE AND HEAMATOLOGICAL ISSUES

1. TUMOUR LYSIS SYNDROME
2. HYPERLEUCOCYTOSIS SYNDROME
3. APPROACH TO FEBRILE NEUTROPENIA
4. OVERVIEW ON MANAGEMENT OF POST-TRANSPLANT PATIENT IN ICU
5. THROMBOTIC MICRO ANGIOPATHY IN ICU: - TTP
6. THROMBOTIC MICRO ANGIOPATHY IN ICU: - HUS
7. MACROPHAGE ACTIVATION SYNDROME / HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) SYNDROME IN ICU
8. ONCOLOGICAL EMERGENCIES PART II - SVC SYNDROME, SPINAL CORD COMPRESSION, PERICARDIAL EFFUSION AND CARCINOMATOSIS MENINGITIS
9. VISCOELASTIC TESTS OF HAEMOSTASIS (TEG AND ROTEM) : WORKING PRINCIPLES AND CLINICAL UTILITIES

## CURRICULUM

(now around 250 topics included)

10. BLEEDING AND COAGULOPATHY IN ICU: HOW TO APPROACH?
11. THROMBOCYTOPENIA / PLATELET DISORDERS IN ICU: DIFFERENTIAL DIAGNOSIS AND APPROACH
12. MANAGING SICKLE CELL CRISIS IN ICU
13. NEWER ANTI COAGULANTS AND DVT
14. STEROIDS IN ICU: WHEN, HOW MUCH AND WHICH PATIENTS?
15. IVIG IN ICU: WHEN, HOW MUCH AND WHICH PATIENTS?

### TRAUMA/BURNS

1. GENERAL VIEW ON ADVANCED TRAUMA LIFE SUPPORT (ATLS)
2. ABDOMINAL TRAUMA
3. TRAUMATIC BRAIN INJURY
4. AN EVIDENCE-BASED MANAGEMENT OF BURNS PATIENT IN ICU

### TOXICOLOGY/SNAKE BITE

1. TOXICOLOGY GENERAL APPROACH
2. APPROACH TO METHEMOGLOBINEMIA IN ICU
3. APPROACH TO CARBON MONOXIDE POISONING IN ICU
4. APPROACH TO PARAQUAT POISONING : AN OVERVIEW
5. APPROACH TO RATOL POISONING (YELLOW / WHITE PHOSPHORUS) : AN OVERVIEW
6. APPROACH TO RATOL :- ALUMINIUM AND ZINC PHOSPHIDE POISONING
7. ICU MANAGEMENT OF PATIENT WITH SNAKE BITE

### PREGNANCY CRITICAL CARE

1. MANAGEMENT OF CRITICALLY ILL PREGNANT PATIENT
2. LIVER DISEASES DURING PREGNANCY: ACUTE FATTY LIVER OF PREGNANCY
3. LIVER DISEASES DURING PREGNANCY: HELLP
4. LIVER DISEASES DURING PREGNANCY: INTRA HEPATIC CHOLESTASIS

### PERI-OPERATIVE CRITICAL CARE

1. MANAGING CRITICALLY ILL POST SURGICAL PATIENT SEPSIS : A PRACTICAL CASE BASED APPROACH
2. MANAGING POST OPERATIVE MYOCARDIAL INFARCTION: PRACTICAL CONSIDERATION
3. MANAGING POSTOPERATIVE PULMONARY EMBOLISM : PRACTICAL CONSIDERATIONS
4. PERI OPERATIVE ARRHYTHMIA

### NEPHRO CRITICAL CARE AND CONNECTIVE TISSUE DISORDERS

1. ACUTE KIDNEY INJURY
2. PRINCIPLES OF RENAL REPLACEMENT THERAPY
3. CITRATE ANTICOAGULATION DURING CRRT: CURRENT EVIDENCE
4. RENAL RESISTIVE INDEX TO PREDICT AKI: METHODOLOGY AND EVIDENCE
5. ROLE OF EXTRACORPOREAL FILTERS (CYTOSORB, OXARIS, TORAYMYXIN AND LPS ADSORBER) IN CRITICALLY ILL PATIENTS : WHERE WE ARE TODAY?
6. DIURETICS IN ICU: WHEN, HOW MUCH AND WHICH PATIENTS?
7. THERAPEUTIC PLASMA EXCHANGE IN ICU: WHAT IS THE EVIDENCE?
8. MANAGING CATASTROPHIC ANTI PHOSPHOLIPID ANTIBODY SYNDROME: ROLE OF INTENSIVIST
9. RHEUMATOLOGICAL EMERGENCIES IN ICU: AN OVERVIEW

### ORGAN CROSSTALKS IN ICU

1. Organ crosstalk in ICU patients: -Cardiorenal syndrome
2. Organ crosstalk in ICU patients: - Pulmonary renal syndrome
3. Organ crosstalk in ICU patients: - Hepatorenal syndrome

## CURRICULUM

(now around 250 topics included)

### ICU ORGANISATION/QUALITY ISSUES/END OF LIFE CARE/IMAGING

1. ICU ORGANISATION AND STRUCTURE : WHAT WE NEED TO UNDERSTAND ?
2. SCORING SYSTEM IN ICU
3. QUALITY INDICATORS IN ICU: AN OVERVIEW
4. HOW TO DO CLINICAL AUDIT IN ICU?
5. COMMUNICATION IN ICU: ITS SHORTFALLS AND HOW TO IMPROVE IT?
6. TRANSPORTING A CRITICALLY ILL PATIENT: PREPARATION AND TROUBLESHOOTING?
7. QUALITY INDICATORS IN ICU: AN OVERVIEW
8. BUNDLE CARE APPROACH IN ICU
9. END OF LIFE CARE PRINCIPLES
10. WHAT IS NEW IN END-OF-LIFE CARE POLICY – INDIAN SCENARIO?
11. HOW TO DO CRITICAL APPRAISAL OF PAPER?
12. IMAGING IN ICU
13. CRITICAL APPRAISAL OF LANDMARK TRIALS IN ICU
13. AN OVERVIEW ON AZTREONAM AVIBACTAM
14. AN OVERVIEW ON HIGH DOSE SULBACTAM
15. AN OVERVIEW ON ECHINOCANDINS: ANIDULAFUNGIN, MICALFUNGIN AND CASPOFUNGIN
16. AN OVERVIEW ON ERTAPENEM
17. AN OVERVIEW ON FAROPENEM
18. AN OVERVIEW ON VORICONAZOLE
19. AN OVERVIEW ON ISAVUCONAZOLE
20. AN OVERVIEW ON POSACONAZOLE
21. AN OVERVIEW ON AMPHOTERICIN -B
22. AN OVERVIEW ON ANTIVIRALS: - ACYCLOVIR
23. AN OVERVIEW ON ANTIVIRALS: - GANCICLOVIR
24. AN OVERVIEW ON ANTIVIRALS: - VALGANCYCLOVIR
25. AN OVERVIEW ON ANTIVIRALS: - FOSCARNET
26. VABORBACTUM AND ITS COMBINATIONS (MEROPENEM-VABORBACTUM): AN OVERVIEW?
27. RELEBACTAM AND ITS COMBINATIONS (IMIPENEM-RELEBACTAM): CURRENT EVIDENCE
28. CLINICAL EVIDENCE ON TANIBORBACTAM COMBINATIONS (CEFEPIME-TANIBORBACTAM)
29. CLINICAL UTILITY AND EVIDENCE ON CEFIDEROCOL
30. DALBAVANCIN: AN OVERVIEW
31. PLAZOMYCIN : AN OVERVIEW

### PRACTICAL POINTS TO REMEMBER ON ANTIBIOTICS, ANTIVIRALS AND ANTIFUNGALS: AN INTENSIVIST PERSPECTIVE

1. AN OVERVIEW ON DOXYCYCLINE, TIGECYCLINE AND MINOCYCLINE
2. AN OVERVIEW ON GLYCOPEPTIDES IN ICU: VANCOMYCIN AND TEICoplanin
3. AN OVERVIEW ON LINEZOLID
4. AN OVERVIEW ON CLINDAMYCIN
5. AN OVERVIEW ON DAPTOMYCIN
6. AN OVERVIEW ON FOSFOMYCIN USE IN ICU
7. AN OVERVIEW ON LEVONADIFLOXACIN: A NOVEL ANTI-MRSA ANTIBIOTIC
8. AN OVERVIEW ON POLYMYXINS IN ICU
9. AN OVERVIEW ON ARBEKACIN
10. AN OVERVIEW ON ROLE OF CEFTRIAXONE SULBACTAM DISODIUM EDETATE IN THE ICU
11. AN OVERVIEW ON CEFTAROLINE
12. AN OVERVIEW ON CEFTAZIDIME AVIBACTAM AND AZTREONAM AVIBACTAM

### NEURO CRITICAL CARE

1. AN OVERVIEW ON ADRENALINE: CURRENT EVIDENCE IN ICU
2. NORADRENALINE: CLINICAL UTILITY AND EVIDENCE
3. DOPAMINE IN ICU: WHEN, WHICH PATIENTS AND HOW MUCH?
4. DOBUTAMINE: IS IT A WONDER IONODILATOR?
5. LEVOSIMENDAN: WHERE IS THE PLACE AMONG CRITICALLY ILL PATIENTS?
6. CLINICAL UTILITY AND CURRENT EVIDENCE ON VASOPRESSIN
7. TERLIPRESSIN IN CRITICAL CARE UNIT: BEYOND ITS ROUTINE USE
8. ANGIOTENSIN II IN VASODILATORY SHOCK: CURRENT EVIDENCE
9. PHENYLEPHRINE: WHEN AND WHICH PATIENTS TO USE?
10. MILRINONE IN MEDICAL ICU: CURRENT EVIDENCE
11. CENTHAQUINE- A NEW MEDICATION FOR HYPOVOLEMIC SHOCK: CURRENT EVIDENCE

## ADDITIONAL TOPICS INCLUDED IN BATCH 12

1. CITRATE ANTICOAGULATION DURING CRRT: CURRENT EVIDENCE
2. HYPOTENSION PREDICTION INDEX (HPI): NEW CONCEPT IN HEMODYNAMIC MONITORING
3. NEW CONCEPT IN HEMODYNAMIC MONITORING: PULSE WAVE TRANSIT TIME
4. RENAL RESISTIVE INDEX TO PREDICT AKI: METHODOLOGY AND EVIDENCE
5. CARBAPENEM RESISTANT ENTEROBACTERIACEAE AND THE OPTIONS AVAILABLE : AN OVERVIEW
6. DALBAVANCIN: AN OVERVIEW
7. PLAZOMYCIN : AN OVERVIEW
8. AVIPTADIL -A SYNTHETIC FORM OF VASOACTIVE INTESTINAL PEPTIDE IN ARDS: CURRENT EVIDENCE
9. CATHETER-RELATED BLOODSTREAM INFECTION (CRBSI) AND CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTION (CLABSI) : AN OVERVIEW
10. INHALED ANTI-INFECTIVES (ANTIBIOTICS AND ANTIFUNGALS) IN ICU : CURRENT EVIDENCE
11. WHAT'S NEW IN THE MANAGEMENT OF ACUTE SEVERE PANCREATITIS IN THE ICU
12. TRALI AND TACO : AN OVERVIEW
13. LIVER DISEASES DURING PREGNANCY: ACUTE FATTY LIVER OF PREGNANCY"
14. LIVER DISEASES DURING PREGNANCY: HELLP"
15. LIVER DISEASES DURING PREGNANCY: INTRA HEPATIC CHOLESTASIS
16. APPROACH TO METHEMOGLOBINEMIA IN ICU
17. APPROACH TO CARBON MONOXIDE POISONING IN ICU
18. APPROACH TO PARAQUAT POISONING : AN OVERVIEW
19. APPROACH TO RODENTICIDE OR RATOL POISONING : AN OVERVIEW"
20. RIGHT VENTRICLE-PROTECTIVE VENTILATION : HOW TO APPROACH"
21. WHAT IS NEW IN ARDS : UNDERSTANDING DIFFERENT PHENOTYPES
22. WHAT IS NEW IN ARDS : ADJUVANT THERAPIES
23. EXTRACORPOREAL CO2 REMOVAL: WHEN AND WHICH PATIENTS?
24. MANAGING HEATSTROKE IN ICU : AN OVERVIEW
25. APPROACH TO AN UNCONSCIOUS PATIENT : AN OVERVIEW"
26. APPROACH TO HYPOGLYCEMIA IN ICU : AN OVERVIEW"
27. APPROACH TO NEW ONSET OF FEVER IN ICU
28. STEPWISE APPROACH TO HYPOXIC RESPIRATORY FAILURE"
29. STEPWISE APPROACH TO HYPERCAPNIC RESPIRATORY FAILURE "
30. MANAGING SICKLE CELL CRISIS IN ICU

SCAN QR CODE TO REGISTER



**COURSE FACULTY & DIRECTOR**

**Dr Harish Mallapura Maheshwarappa**

MBBS, MD, DNB, IDCCM, DM (Critical Care Medicine TMH, Mumbai),  
EDIC(Dublin), Fellowship in Infectious Diseases, FIARC, MBA

**Intensive Care Physician and Infectious Disease Specialist**

Mail : [dr.harishmm@rocketmail.com](mailto:dr.harishmm@rocketmail.com)

Call : +91-80952 18493

For technical assistance: Mr Anil - +91-95381 15187



**FEE STRUCTURE**

CATEGORY		FOR FIRST 100 REGISTRATIONS - 25% DISCOUNT TILL 31st DECEMBER 2024	15% EXTENDED DISCOUNT- 31ST DECEMBER TO 15TH JANUARY 2025	REGULAR - WITHOUT DISCOUNT-15TH JANUARY ONWARDS
INDIAN DELEGATES (INR)	Registration fee	30000	30000	30000
	Discount	7500	4500	0
	Amount after discount	22500	25500	30000
	GST 18%	4050	4590	5400
	<b>Total amount payable</b>	<b>26550</b>	<b>30090</b>	<b>35400</b>
FOREIGN DELEGATES (USD)	Registration fee	365	365	365
	Discount	90	55	0
	Amount after discount	275	310	365
	GST 18%	50	55	65
	<b>Total amount payable</b>	<b>325</b>	<b>365</b>	<b>430</b>

CLASSES WILL BE STARTING FROM  
**JANUARY 2025**